Bitran J D, Brown C, Desser R K, Kozloff M F, Shapiro C, Billings A A
J Surg Oncol. 1981;16(3):273-7. doi: 10.1002/jso.2930160312.
The results of treatment with intracavitary bleomycin are reported in twenty patients with a malignant pleural effusion and five patients with malignant ascites. The control rate was 17/20 (85%) patients with malignant pleural effusions and 3/5 (60%) patients with malignant ascites. Toxicities were minimal with fever being the most common side effect in four patients (16%. Bleomycin is an effective and nontoxic sclerosing agent.
